Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 15:337:44-51.
doi: 10.1016/j.ijcard.2021.05.016. Epub 2021 May 13.

Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial

R Heggie  1 , A Briggs  2 , B Stanley  3 , R Good  4 , P Rocchiccioli  5 , M McEntegart  5 , S Watkins  4 , H Eteiba  4 , A Shaukat  4 , M Lindsay  4 , K Robertson  4 , S Hood  4 , R McGeoch  6 , R McDade  4 , E Yii  7 , D Collison  5 , K Oldroyd  5 , T J Ford  8 , C Berry  9
Affiliations
Free article

Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial

R Heggie et al. Int J Cardiol. .
Free article

Abstract

Aim: Coronary angiography is indicated in many patients with known or suspected angina for the investigation of coronary artery disease (CAD). However, up to half of patients with symptoms of ischaemia have no obstructive coronary arteries (INOCA). This large subgroup includes patients with suspected microvascular angina (MVA) and/or vasospastic angina (VSA). Clinical guidelines relating to the management of patients with INOCA are limited. Uncertainty regarding the diagnosis of patients with INOCA presents a health economic challenge, both in terms of healthcare resource utilisation and of quality-of-life impact on patients.

Methods: A cost-effectiveness analysis of the introduction of stratified medicine into the invasive management of INOCA, based on clinical and resource-use data obtained in the CorMicA trial, from a UK NHS perspective. The intervention included an invasive diagnostic procedure (IDP) of coronary vascular function during coronary angiography to define clinical endotypes to target with linked medical therapy. Outcomes of interest were mean total cost and QALY gain between treatment groups, and the incremental cost-effectiveness ratio. We undertook probabilistic sensitivity and scenario analyses.

Results: The incremental cost per QALY gained at 12 months was £4500 (£2937, £33264). Compared with a willingness-to-pay (WTP) threshold of £20,000 per QALY, the use of the IDP test is cost-effective. At this WTP threshold there is a 96% probability of the IDP being cost-effective, based on the uncertainty described by bootstrap analysis.

Conclusions: The burden of INOCA, particularly in women, is known to be significant. These findings provided new evidence to inform this unmet clinical need.

Keywords: Cost-effectiveness; INOCA; Stratified medicine.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest A.B., B.S., R.G., H.E., A.S., M.M.L., S.H., E.Y., R.McD. have no relevant disclosures. C·B. is employed by the University of Glasgow which holds consultancy and research agreements with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Coroventis, GSK, HeartFlow, Menarini, Neovasc, and Siemens Healthcare. K.G.O. has received consultant and speaker fees from Abbott Vascular and Boston Scientific. He is employed by Biosensors. S.W. has received consultant and speaker fees from Boston Scientific. P.R. has received consultant and speaker fees from Astra Zeneca. K.R has received educational support from Abbott Vascular and speaker fees from Astra Zeneca. RMT has acted as an advisor for Novartis. MME has a proctoring agreement with Boston Scientific and Vascular Perspectives. T.F. and DC have received speakers fees from Abbott Vascular.

Comment in